stimulant
drug that increases the activity of the central nervous system
≈ 11 min read
stimulant. encyclopegia.org, snapshot stimulant-024889-3615f78f1e424d1b. /a/stimulant
Names in other languages
- nansèng-hùn-che
- Englishstimulant
- Polskistymulant
- 中文兴奋剂
- 简体中文兴奋剂
- 繁體中文興奮劑
- 中文興奮劑
- 中文兴奋剂
- 中文興奮劑
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
20 mg sustained-release tablets Stimulants (also called as central nervous system stimulant, psychostimulant, or colloquially an upper) are a class of psychoactive drugs that increase alertness. They are used for various purposes, such as enhancing attention, motivation, cognition, mood, and physical activity. Some stimulants occur in nature while others are synthetic.
Common stimulants include caffeine, nicotine, cocaine, amphetamine, methamphetamine, methylphenidate, and modafinil. Some stimulants are subject to governmental regulation or prohibition because they can have adverse side effects including addiction, drug tolerance, drug withdrawal, psychosis, anxiety, insomnia, cardiovascular disease, and neurotoxicity.
The misuse or abuse of stimulants can have serious adverse health and social consequences, such as overdose, substance dependence, crime, and violent behavior. Stimulants increase activity in the sympathetic nervous system. They often increase synaptic concentrations of excitatory neurotransmitters, particularly norepinephrine and dopamine.
Other stimulants work by binding to the receptors of excitatory neurotransmitters (e.g., nicotine) or by blocking the activity of endogenous agents that promote sleep (e.g., caffeine). Stimulants can affect various functions, including arousal, attention, the reward system, learning, memory, and emotion.
Effects range from mild stimulation to euphoria, depending on the specific drug, dose, route of administration, and inter-individual characteristics. Stimulants have a long history of use, both for medical and non-medical purposes.
Archeological evidence from Peru shows that cocaine use dates back as far as 8000 B.C.E. Stimulants have been used to treat various conditions, such as narcolepsy, attention deficit hyperactivity disorder (ADHD), obesity, depression, and fatigue. They have also been used as recreational drugs, performance-enhancing substances, cognitive enhancers, and to promote aggression of combatants in wartime.
Acute
Stimulants in low doses, such as those prescribed to treat attention deficit hyperactivity disorder (ADHD), increase ability to focus, vigor, sociability, wakefulness, libido and may elevate mood or cause euphoria. However, in higher doses, stimulants may actually decrease the ability to focus, a principle of the Yerkes–Dodson law.
Many, but not all, stimulants have ergogenic effects; that is, they enhance physical performance. Drugs such as ephedrine, pseudoephedrine, amphetamine, and methylphenidate have well documented ergogenic effects, while cocaine has the opposite effect.
Neurocognitive enhancing effects of stimulants, specifically modafinil, amphetamine, and methylphenidate have been reported in healthy adolescents by some studies, and is a commonly cited reason among illicit drug users for use, particularly among college students in the context of studying. Still, results of these studies is inconclusive: assessing the potential overall neurocognitive benefits of stimulants among healthy youth is challenging due to the diversity within the population, the variability in cognitive task characteristics, and the absence of replication of studies.
Research on the cognitive enhancement effects of modafinil in healthy non-sleep-deprived individuals has yielded mixed results, with some studies suggesting modest improvements in attention and executive functions while others show no significant benefits or even a decline in cognitive functions. In some cases, psychiatric phenomena may emerge such as stimulant psychosis, paranoia, and suicidal ideation.
Acute toxicity has been reportedly associated with hyperhidrosis, panic attacks, severe anxiety, mydriasis, paranoia, aggressive behavior, psychosis, rhabdomyolysis, and punding. The violent and aggressive behavior associated with acute stimulant toxicity may partially be driven by paranoia.
Most drugs classified as stimulants are sympathomimetic, meaning that they stimulate the sympathetic branch of the autonomic nervous system. This stimulation leads to effects such as mydriasis (dilation of the pupils), increased heart rate, blood pressure, respiratory rate and body temperature.
When these changes become pathological, they are called arrhythmia, hypertension, and hyperthermia, and may lead to rhabdomyolysis, stroke, cardiac arrest, or seizures. However, given the complexity of the mechanisms that underlie these potentially fatal outcomes of acute stimulant toxicity, it is impossible to determine what dose may be lethal.
Chronic
Assessment of the effects of stimulants is relevant given the large population currently taking stimulants. A 2022 meta-analysis with a sample size of just under four million people found no association between the use of prescription stimulants and the development of cardiovascular disease in any age group.
A review of a year long period of prescription stimulant use in those with attention deficit hyperactivity disorder (ADHD) found that cardiovascular side effects were limited to transient increases in blood pressure only. However, a 2024 systematic review of the evidence found that stimulants overall improve ADHD symptoms and broadband behavioral measures in children and adolescents, though they carry risks of side effects like appetite suppression and other adverse events.
Initiation of stimulant treatment in those with ADHD in early childhood appears to carry benefits into adulthood in social and cognitive functioning, and appears to be relatively safe. Abuse of prescription stimulants (not following physician instruction) or of illicit stimulants carries many negative health risks.
Abuse of cocaine, depending upon route of administration, increases risk of cardiorespiratory disease, stroke, and sepsis. Some effects are dependent upon the route of administration, with intravenous use associated with the transmission of many disease such as hepatitis C, HIV/AIDS, and potential medical emergencies such as infection, thrombosis, or pseudoaneurysm, while inhalation may be associated with increased lower respiratory tract infection, lung cancer, and pathological restricting of lung tissue.
Cocaine may also increase risk for autoimmune disease and damage nasal cartilage. Abuse of methamphetamine produces similar effects as well as marked degeneration of dopaminergic neurons, resulting in an increased risk for Parkinson's disease.
Depression
Stimulants were one of the first classes of drugs to be used in the treatment of major depressive disorder, beginning after the introduction of the amphetamines in the 1930s. However, they were largely abandoned for treatment of depression following the introduction of conventional antidepressants in the 1950s.
Subsequent to this, there has been a resurgence in interest in stimulants for depression in recent years. Stimulants produce a fast-acting and pronounced but transient and short-lived mood lift. In relation to this, they are minimally effective in the treatment of depression when administered continuously.
In addition, tolerance to the mood-lifting effects of amphetamine has led to dose escalation and dependence. Although the efficacy for depression with continuous administration is modest, it may still reach statistical significance over placebo and provide benefits similar in magnitude to those of conventional antidepressants.
The reasons for the short-term mood-improving effects of stimulants are unclear, but may relate to rapid tolerance. Tolerance to the effects of stimulants has been studied and characterized both in animals and humans. Stimulant withdrawal is remarkably similar in its symptoms to those of major depressive disorder.
Cocaine analogs
Hundreds of cocaine analogs have been created, all of them usually maintaining a benzyloxy connected to the 3 carbon of a tropane. Various modifications include substitutions on the benzene ring, as well as additions or substitutions in place of the normal carboxylate on the tropane 2 carbon. Various compound with similar structure activity relationships to cocaine that aren't technically analogs have been developed as well.
Mechanisms of action
Most stimulants exert their activating effects by enhancing catecholamine neurotransmission. Catecholamine neurotransmitters are employed in regulatory pathways implicated in attention, arousal, motivation, task salience and reward anticipation.
Classical stimulants either block the reuptake or stimulate the efflux of these catecholamines, resulting in increased activity of their circuits. Some stimulants, specifically those with entactogenic and hallucinogenic effects, also affect serotonergic transmission.
Some stimulants, such as some amphetamine derivatives and yohimbine, can decrease negative feedback by antagonizing regulatory autoreceptors. Adrenergic agonists, such as, in part, ephedrine, act by directly binding to and activating adrenergic receptors, producing sympathomimetic effects. There are also more indirect mechanisms of action by which a drug can elicit activating effects.
Caffeine is an adenosine receptor antagonist, and only indirectly increases catecholamine transmission in the brain. Pitolisant is an histamine 3 (H 3 )-receptor inverse agonist. As histamine 3 (H 3 ) receptors mainly act as autoreceptors, pitolisant decreases negative feedback to histaminergic neurons, enhancing histaminergic transmission.
The precise mechanism of action of some stimulants, such as modafinil, for treating symptoms of narcolepsy and other sleep disorders, remains unknown.
Modafinil
Modafinil is an eugeroic medication, which means that it promotes wakefulness and alertness. Modafinil is sold under the brand name Provigil among others. Modafinil is used to treat excessive daytime sleepiness due to narcolepsy, shift work sleep disorder, or obstructive sleep apnea.
While it has seen off-label use as a purported cognitive enhancer, the research on its effectiveness for this use is not conclusive. Despite being a CNS stimulant, the addiction and dependence liabilities of modafinil are considered very low. Although modafinil shares biochemical mechanisms with stimulant drugs, it is less likely to have mood-elevating properties.
The similarities in effects with caffeine are not clearly established. Unlike other stimulants, modafinil does not induce a subjective feeling of pleasure or reward, which is commonly associated with euphoria, an intense feeling of well-being. Euphoria is a potential indicator of drug abuse, which is the compulsive and excessive use of a substance despite adverse consequences.
In clinical trials, modafinil has shown no evidence of abuse potential, that is why modafinil is considered to have a low risk of addiction and dependence, however, caution is advised.
Pitolisant
Pitolisant is an inverse agonist (antagonist) of the histamine H 3 autoreceptor. As such, pitolisant is an antihistamine medication that also belongs to the class of CNS stimulants. Pitolisant is also considered a medication of eugeroic class, which means that it promotes wakefulness and alertness.
Pitolisant is the first wakefulness-promoting agent that acts by blocking the H 3 autoreceptor. Pitolisant has been shown to be effective and well-tolerated for the treatment of narcolepsy with or without cataplexy. Pitolisant is the only non-controlled anti-narcoleptic drug in the United States.
It has shown minimal abuse risk in studies. Blocking the histamine H 3 autoreceptor increases the activity of histamine neurons in the brain. The H 3 autoreceptors regulate histaminergic activity in the central nervous system (and to a lesser extent, the peripheral nervous system) by inhibiting histamine biosynthesis and release upon binding to endogenous histamine.
By preventing the binding of endogenous histamine at the H 3 , as well as producing a response opposite to that of endogenous histamine at the receptor (inverse agonism), pitolisant enhances histaminergic activity in the brain.
Serotonin 5-HT 2A receptor agonists
Certain serotonergic psychedelics and related non-hallucinogenic drugs, acting as serotonin 5-HT 2A receptor agonists, have been reported to have mild stimulant and/or "psychic energizing" (i.e., acute antidepressant) effects, both in animals and humans. These effects are often present at low or sub-hallucinogenic doses.
Psychedelics are also known to promote wakefulness or cause insomnia. Psychedelic and related drugs that have been reported to produce stimulant effects include the phenethylamines 2,5-DMA (DOH), DOM, DOET, DOPR, DON, MTFEM, Ariadne (4C-DOM; BL-3912; Dimoxamine), 2C-B, 2C-D, 2C-G-N, and ASR-2001 (2CB-5PrO), and the tryptamines 5-MeO-DiPT and 5-MeO-MiPT, among others.
The lysergamide LSD has also been reported to have mild stimulant effects. Conversely, psilocybin does not seem to produce the same stimulant effects.
The non-hallucinogenic Ariadne was under development as a potential pharmaceutical drug to take advantage of such effects in the treatment of conditions like depression in the 1970s, and reached phase 3 clinical trials for such indications, but was shelved reportedly for strategic economic reasons. ASR-2001, which is likewise non-hallucinogenic, is under development for use as a stimulant-like medication for treatment of psychiatric disorders.
Serotonin 5-HT 2A receptor agonists have been found to increase dopamine levels in brain areas like the frontal cortex, striatum, and nucleus accumbens in animal studies. Relatedly, serotonin 5-HT 2A receptor agonists are known to produce stimulant-like effects in animals such as hyperlocomotion (increased locomotor activity) and pro-motivational effects.
The serotonin 5-HT 2C receptor, which most psychedelics additionally activate to varying degrees, is known to have opposing effects on dopamine release and stimulant-related behavior, which may contribute to inverted U-shaped dose–response relationships as well as divergent stimulant-like effects between different psychedelics.
Treatment for misuse
Psychosocial treatments, such as contingency management, have demonstrated improved effectiveness when added to treatment as usual consisting of counseling or case-management. This benefit is demonstrated by a decrease in dropout rates and a lengthening of periods of abstinence.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1378701469 under CC BY-SA 4.0; modifications have been made.